Equities

Bayer AG

Bayer AG

Actions
Health CarePharmaceuticals & Biotechnology
  • Price (EUR)102.40
  • Today's Change-2.64 / -2.51%
  • Shares traded1.44m
  • 1 Year change-13.26%
  • Beta1.0299
Data delayed at least 15 minutes, as of May 23 2018 13:17 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Bayer AG had relatively flat revenues (34.94bn to 35.02bn), though the company grew net income 61.91% from 4.53bn to 7.34bn. A reduction in the cost of goods sold as a percentage of sales from 33.64% to 32.51% was a component in the net income growth despite flat revenues.
Gross margin67.21%
Net profit margin10.12%
Operating margin16.78%
Return on assets4.35%
Return on equity10.22%
Return on investment5.56%
More ▼

Cash flow in EURView more

In 2017, Bayer AG increased its cash reserves by 299.21%, or 5.68bn. The company earned 8.13bn from its operations for a Cash Flow Margin of 23.23%. In addition the company used 432.00m on investing activities and also paid 1.88bn in financing cash flows.
Cash flow per share7.12
Price/Cash flow per share14.51
Book value per share46.35
Tangible book value per share15.31
More ▼

Balance sheet in EURView more

Bayer AG has a Debt to Total Capital ratio of 26.77%, a lower figure than the previous year's 43.99%.
Current ratio2.53
Quick ratio2.04
Total debt/total equity0.3662
Total debt/total capital0.2677
More ▼

Growth rates in EUR

Year on year, growth in dividends per share increased 3.70% while earnings per share excluding extraordinary items fell by -17.14%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is in-line with the industry average.
Div yield(5 year avg)1.89%
Div growth rate (5 year)8.06%
Payout ratio (TTM)62.98%
EPS growth(5 years)5.09
EPS (TTM) vs
TTM 1 year ago
-6.26
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.